Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
MTNB 
Matinas BioPharma Holdings Inc (MTNB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: MTNB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -50.68% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.06M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 2 | Beta 1.33 | 52 Weeks Range 0.47 - 3.09 | Updated Date 12/6/2025 |
52 Weeks Range 0.47 - 3.09 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-11-11 | When - | Estimate - | Actual -0.3955 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.81% | Return on Equity (TTM) -151.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1705565 | Price to Sales(TTM) 46.5 |
Enterprise Value 1705565 | Price to Sales(TTM) 46.5 | ||
Enterprise Value to Revenue 37.2 | Enterprise Value to EBITDA -1.79 | Shares Outstanding 6406191 | Shares Floating 5232897 |
Shares Outstanding 6406191 | Shares Floating 5232897 | ||
Percent Insiders 22.11 | Percent Institutions 5.33 |
Upturn AI SWOT
Matinas BioPharma Holdings Inc
Company Overview
History and Background
Matinas BioPharma Holdings Inc. was founded in 2011. It focuses on developing innovative therapies using its Lipid Nano-Crystal (LNC) platform technology to overcome challenges associated with oral delivery of drugs.
Core Business Areas
- LNC Platform Technology: The core of Matinas' business is its LNC platform, which is designed to improve the oral bioavailability and targeted delivery of drugs. The LNC platform is being used to develop new formulations of existing drugs, as well as to deliver novel therapeutics.
Leadership and Structure
The leadership team includes Jerome D. Jabbour (CEO), Terri Matkovits (CFO), and various VPs leading clinical, regulatory, and commercial strategy.
Top Products and Market Share
Key Offerings
- LYPDROCA (oral amphoterecin B): LYPDROCA is an oral formulation of amphotericin B for the treatment of invasive fungal infections. Currently, it is in Phase 3 trials. Market share data is not yet available as it is not currently an approved product. Competitors include IV Amphotericin B formulations and other antifungals such as azoles.
- MAT2203 (oral voriconazole): MAT2203 is an oral formulation of voriconazole, also utilizing the LNC platform. It is in preclinical development. Market share data is unavailable. Competitors are IV and oral voriconazole generics and brands like Vfend.
Market Dynamics
Industry Overview
The pharmaceutical industry is competitive and innovative, driven by the need for novel treatments and improved drug delivery methods. Significant demand exists for orally available formulations of traditionally IV-administered drugs.
Positioning
Matinas BioPharma is positioned as an innovator in oral drug delivery using its LNC platform. Its competitive advantage lies in its ability to enhance the bioavailability and targeted delivery of drugs that are typically administered intravenously.
Total Addressable Market (TAM)
The TAM for antifungal drugs and oral drug delivery systems is estimated to be several billion dollars annually. Matinas is positioned to capture a portion of this TAM with successful commercialization of LYPDROCA and other LNC-based products.
Upturn SWOT Analysis
Strengths
- Proprietary LNC drug delivery platform
- Potential for oral delivery of traditionally IV drugs
- Experienced leadership team
- Focused development pipeline
Weaknesses
- Reliance on LNC platform success
- Limited commercial products currently
- High research and development costs
- Dependence on successful clinical trials
Opportunities
- Expansion of LNC platform to new drugs
- Partnerships with larger pharmaceutical companies
- Address unmet medical needs with oral formulations
- Potential for orphan drug designation
Threats
- Clinical trial failures
- Competition from existing therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- GILD
- VRX
- MYL
Competitive Landscape
Matinas faces competition from established pharmaceutical companies with broader pipelines and commercial infrastructure. Its advantage lies in its LNC platform technology, which could provide superior drug delivery and patient outcomes compared to existing therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by advancements in its clinical trials and preclinical work with LNC platform and associated partnerships.
Future Projections: Future growth is dependent on the successful completion of clinical trials, regulatory approvals, and commercial launch of LYPDROCA and other products.
Recent Initiatives: Recent initiatives include advancing LYPDROCA through Phase 3 clinical trials and expanding the preclinical pipeline.
Summary
Matinas BioPharma is a clinical-stage biopharmaceutical company leveraging its LNC platform to develop oral formulations of drugs. Its success hinges on the positive outcomes of clinical trials, particularly LYPDROCA. The company is currently pre-revenue, so it needs to be cautious about spending. While its LNC technology is promising, the company faces challenges from larger competitors and regulatory hurdles.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Investment decisions should be made with the advice of a qualified financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Matinas BioPharma Holdings Inc
Exchange NYSE MKT | Headquaters Bedminster, NJ, United States | ||
IPO Launch date 2014-08-18 | Co-Founder, Chairman, CEO and President Mr. Jerome D. Jabbour J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.matinasbiopharma.com |
Full time employees 3 | Website https://www.matinasbiopharma.com | ||
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.